The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update

Marina Boccardi1,2 · Alessandra Dodich3,4 · Emiliano Albanese5 · Angèle Gayet-Ageron6 · Cristina Festari7 · Nicholas J. Ashton8,9,10,11 · Gérard N. Bischof12 · Konstantinos Chiotis13,14 · Antoine Leuzy13 · Emma E. Wolters15 · Martin A. Walter16 · Gil D. Rabinovici17 · Maria C. Carrillo18 · Alexander Drzezga19,20,21 · Oskar Hansson22,23 · Agneta Nordberg13,24 · Rik Ossenkoppele15,25 · Victor L. Villemagne26,27 · Bengt Winblad24,28 · Giovanni B. Frisoni2,29 · Valentina Garibotto3,16

Received: 25 September 2020 / Accepted: 15 November 2020 / Published online: 10 March 2021
© The Author(s) 2021

Abstract

Background The 2017 Alzheimer’s disease (AD) Strategic Biomarker Roadmap (SBR) structured the validation of AD diagnostic biomarkers into 5 phases, systematically assessing analytical validity (Phases 1–2), clinical validity (Phases 3–4), and clinical utility (Phase 5) through primary and secondary aims. This framework allows to map knowledge gaps and research priorities, accelerating the route towards clinical implementation. Within an initiative aimed to assess the development of biomarkers of tau pathology, we revised this methodology consistently with progress in AD research.

Methods We critically appraised the adequacy of the 2017 Biomarker Roadmap within current diagnostic frameworks, discussed updates at a workshop convening the Alzheimer’s Association and 8 leading AD biomarker research groups, and detailed the methods to allow consistent assessment of aims achievement for tau and other AD diagnostic biomarkers.

Results The 2020 update applies to all AD diagnostic biomarkers. In Phases 2–3, we admitted a greater variety of study designs (e.g., cross-sectional in addition to longitudinal) and reference standards (e.g., biomarker confirmation in addition to clinical progression) based on construct (in addition to criterion) validity. We structured a systematic data extraction to enable transparent and formal evidence assessment procedures. Finally, we have clarified issues that need to be addressed to generate data eligible to evidence-to-decision procedures.

Discussion This revision allows for more versatile and precise assessment of existing evidence, keeps up with theoretical developments, and helps clinical researchers in producing evidence suitable for evidence-to-decision procedures. Compliance with this methodology is essential to implement AD biomarkers efficiently in clinical research and diagnostics.

Keywords Biomarker · Alzheimer’s disease · Dementia · MCI · Mild cognitive impairment · Validation methodology

Introduction

In 2014–2017, an international effort proposed the Strategic Biomarker Roadmap (SBR) as a methodological framework to improve the cost-effectiveness of the validation of Alzheimer’s disease (AD) (see Table 1 for a Glossary of terms used in this article) diagnostic biomarkers and facilitate regulators’ approval, refund, and implementation in daily practice [13]. This initiative consisted of adapting to the AD field, a methodological framework successfully used to validate diagnostic biomarkers in oncology [14], after adaptation from the methodology of drug development [15].

The SBR structures and the validation of AD diagnostic biomarkers into a systematic sequence of 5 phases each encompass primary and secondary aims. Phases 1–2 entail the assessment of analytical validity, Phases 3–4 clinical validity, and Phase 5 clinical utility. The framework specifies appropriate study designs, sample sizes, population, and gold- or admissible reference standards for each primary and secondary aim [14, 15]. Complying with the SBR logical sequence and methods increases the cost-effectiveness of validation
studies by reducing errors of many kinds. For example, fulfilling all aims of analytical validity within Phase 2 allows to minimize the large amount of variability due to heterogeneous sampling procedures. Such variability was up to fivefold in the example of hippocampal segmentation with different protocols [16]. It cannot be amended post hoc and eventually results in the inability of the published data to enter formal evidence-to-decision (EtD) procedures and support evidence-based clinical or policy decision-making. An example for such failure is provided by the field of FDG-PET: the Cochrane review analyzing the extensive literature on its diagnostic accuracy in detecting AD in MCI patients found exceedingly large variability of results and concluded that no clinical recommendation could be issued based on such data [17].

Appraising the validation status of diagnostic biomarkers based on the SBR framework helps to map the validation steps that are properly completed, those in need of further confirmation, and the gaps requiring urgent investigation, before proceeding and collecting additional data that would otherwise lack validity, being based on faulty premises. Thus, complying with this methodology helps generating data eligible to formal EtD procedures [18], i.e., objective and transparent decision-making procedures for clinical or policy contexts, that can be based on available literature transparently and directly, with minimum intervention by expert panels. EtD ineligibility leads, on the other side, to the need of consensus by experts, who can only make decisions based on individual expertise and on the available, but faulted, data.

Table 1 Glossary detailing the meaning of the terms used in the 2020 Strategic Biomarker Roadmap

| Glossary                          | Definition                                                                                     |
|-----------------------------------|------------------------------------------------------------------------------------------------|
| Alzheimer’s disease               | We consider Alzheimer’s disease (AD) as the presence of extracellular amyloid-β plaques and aggregates of hyper-phosphorylated tau in neurofibrillary tangles, independently of the clinical expression of cognitive symptoms [1] |
| AD dementia                       | AD dementia denotes an acquired, insidious, and progressive cognitive and functional impairment due to AD, as defined in the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria [2, 3]. However, a significant proportion (up to 30%) of AD dementia cases based on clinical criteria might have non-AD pathology [4–6] |
| Analytical validity               | Ability of the assay (i.e., the ascertainment method used) to detect and/or quantify the biological or molecular target entity |
| Assay                             | Analytic procedure and methods measuring the presence, amount, or functional activity of a target entity |
| Clinical stage                    | The terms dementia, MCI, or prodromal denote the stage of clinical impairment and can relate to different pathophysiology |
| Construct validity                | Degree to which a measure agrees with a theoretical construct. It entails the construct, i.e., the theory and current model of the target disorder, and the appropriateness of the inferential reasoning |
| Criterion validity                | Extent to which a measure relates to other measures (concurrent validity). Criterion validity is tested against a gold standard |
| Mild cognitive impairment (MCI)   | MCI refers to a population without, or with subtle, functional disability, but with an acquired objective cognitive impairment. Representing a clinical syndrome, it encompasses cases progressing to AD (about 50%) or non-AD dementia (about 10–15%) [7–10] as well as stable cases (about 35–40%). MCI cases positive to AD biomarkers can be defined as prodromal AD or MCI due to AD based on research diagnostic criteria [11, 12] and consistently also with the 2018 A/T/N framework [1]. The diagnosis of AD at the MCI stage represents the focus of the present review |
| Non-AD neurodegenerative disease  | This term refers to all neurodegenerative disorders considered for the differential diagnosis, including a large pathological spectrum, e.g., hippocampal sclerosis, limbic-predominant age-related TDP-43, encephalopathy, frontotemporal lobar degeneration, Lewy body disease, and multiple system atrophy |
| Pathophysiology                   | We use the terms AD and non-AD to denote the pathological presence or absence of amyloid-β plaques and aggregates of hyper-phosphorylated tau in neurofibrillary tangles |
| Test                              | Use of the assay to determine whether an individual is positive or negative to the target disease. It can be based on a continuous variable, with cutoffs used to define positivity, negativity, and gray zone |
In 2017, we used this framework to assess the validation status of the neuropsychological assessment (viz., episodic memory test) as a gateway to biomarker-based diagnosis [19], and of most consolidated AD biomarkers at that time, i.e., amyloid imaging [20], CSF [21], hippocampal atrophy [22], FDG-PET [23], and biomarkers for dementia with Lewy bodies [24], based on evidence published until 2015. In the present work, we revised the SBR to update it to the current A/T/N framework for research on AD and related disorders [1] and to enable proper assessment of biomarkers of tau pathology [25–29]. Such update was required, in that the diagnostic criteria adopted in 2017 entailed a relatively unclear role of Tau in the diagnostic procedure of AD. Instead, the new A/T/N framework [1] (a) requires tau positivity to formulate a diagnosis of clinical AD (AD dementia, or MCI due to AD, as opposed to Alzheimer’s pathologic change defined by biomarkers), and (b) depicts cases with positive tau and negative Aβ as belonging to a non-AD, but still to a dementing neurodegenerative disorders continuum that is relevant to the clinical aim of providing patients with accurate and timely diagnosis. These features can impact the kind of required or admissible gold/reference standards and the design of validation studies, as well as the exact meaning of positive tau biomarkers in the diagnostic procedure, thus requiring to check and possibly revise some aspects of the 2017 SBR.

Methods

This work is part of a wider initiative, aimed to use the SBR and assess the validation status of biomarkers of tau pathology [25–29]. The initiative consisted of a workshop held in Geneva, November 11–12, 2019. The PI (Valentina Garibotto) convened the Alzheimer’s Association and 8 expert groups on AD biomarker research, namely, those led by Giovanni Frisoni, Alexander Drzezga, Oskar Hansson, Agneta Nordberg, Rik Ossenkoppele, Gil D. Rabinovici, Victor L. Villemagne, and Bengt Winblad. Within this wider initiative, this work aimed to define the methodology allowing some of these expert groups to assess the validation status of AD biomarkers consistently, in line with the theoretical development of the AD field. To provide such updated methodology, we discussed the adequacy of the 2017 SBR methods specified for each phase’s primary and secondary aim with dedicated methodologists (EA, AGA). We dedicated specific attention to the features of the biomarkers of tauopathy, which were just being developed during the previous SBR initiative (2014–2017) and to the new AD research diagnostic criteria [1]. We have then formulated an updated proposal, which was presented and discussed at the Geneva workshop. The general discussion contributed to clarify the issues entailed in the current scenario of AD biomarker development, fix required updates, and outline needs for future developments. Four of the participant expert groups (viz., those led by Agneta Nordberg, Oskar Hansson, Rik Ossenkoppele, and Alexander Drzezga) have then assessed the validation status of CSF-, plasma- and imaging-tau AD biomarkers based on the evidence published until July 2020. Research strings and specific methods are reported in the five dedicated reviews [25–29].

In addition to the revision of the SBR methodology, we have also provided updates on the assessment of aim achievement within the dedicated reviews. Such updates were defined based on preliminary data on the validation status of biomarkers of tauopathy and on other methodological considerations, in particular the fact that the same groups involved in biomarker development were assessing the available studies.

Results

Most of the methods used in 2017 were still appropriate to assess biomarker of tauopathy and other biomarkers within the A/T/N framework. The aspects that required adjustment included the definition of the study design eligible to assess aim achievement, the admitted reference standards for Phases 2–4, the formal data extraction for the evidence assessment, and edits to the definition of aim achievement. Below we detail these aspects along with the other key features of the initiative consistent with 2017.

Context of use (purpose, population, and nature of disease)

As in 2017, the context of use remains the diagnosis in people referred or autonomously referring to memory clinics for cognitive complaints. The aim of this context of use consists of using biomarkers to detect AD and, primarily, identify people whose impairment is likely to progress to a dementia stage; consistently, we use “progression at follow-up” as a reference standard for the biomarker. However, we underline that despite this perspective and methods, the aim of the SBR is to validate diagnostic, and not prognostic biomarkers. Consistent with 2017, only patients with objective impairment at formal cognitive assessment would access the full diagnostic workup, and we focus on the MCI stage.

Context of use: 2020 update Relative to the target disorder, we keep referring primarily to AD, namely, to the neurodegenerative dementing disorder characterized by brain amyloidosis and tauopathy, consistent with the 2018 A/T/N framework [1]. In this case, the difference from the 2017 framework regards the theoretical research construct behind the definition of AD as a pathophysiological disorder, although it does not affect the clinical picture of the target disorder, nor the formal gold standards, that should ideally entail both clinical progression at follow-up examination and confirmation at pathology.
However, within the A/T/N framework, the tau biomarkers can also detect patients with non-AD neurodegenerative disorders. This option is therefore now expressly included by our initiative. It is consistent with the use of clinical progression as a reference standard and with the ultimate aim of detecting patients with dementing neurodegenerative disorders in clinical practice.

**Analytical validity** (See Table 1 for a Glossary of terms) The primary and secondary aims of Phases 1–2 studies are the same as in the 2017 assessment (Table 2). Briefly, analytical validity relates to the ability of the assay, that may be later used as a diagnostic test, to detect the alteration of interest. Thus, the gold standard for Phases 1–2 studies is pathology, and the primary and secondary aims are set to determine the features of the assay in order to ascertain its potential usefulness as a diagnostic test and to specify standard operating procedures to guarantee informative and reliable measurements within and across laboratories.

**Analytical validity: 2020 update** In this update, we admitted that some Phase 2 studies could have only progression at follow-up, or other reference standard like positivity to a different AD biomarker, as an acceptable reference standard, due to the fact that brain histology is usually not accessible at the time of the biomarker assessment. However, this should be considered with warning of methodological fault for Phase 2 studies, and producing evidence-based on proper gold standard should anyway be considered a research priority (see asterisk in Fig. 1 and Table 2).

**Clinical validity** Clinical validity, assessed in Phases 3–4 studies, is aimed to use the assay defined in Phases 1–2 as a test to detect the target disease and to assess its diagnostic performance (sensitivity, specificity, likelihood ratios, and area under the curve). The primary and secondary aims of Phase 3 are intended to adjust the test features and its use in the diagnostic procedure, e.g., to define thresholds by accounting for covariates as assessed in Phase 2 and to achieve the desired discrimination accuracy. In order to tune the diagnostic test based on the data from the essay, covariates, the desired discrimination accuracy, and the other basic properties, all studies in Phase 3 are performed in strictly controlled experimental conditions. Thus, even when patients come from memory clinics, the biomarker itself is not used to formulate their clinical diagnosis, but is only collected for research purposes. The biomarker’s features are thus assessed and adjusted, to prepare its use in Phase 4 studies. In Phase 4, the biomarker is tested in real clinical contexts where it is also used to support clinical diagnosis for patients, although within a research framework. Therefore, the information collected in Phase 4 studies informs about the diagnostic performance of the biomarker in real-world contexts, where patients are not strictly selected and may have a variety of comorbidities, diagnostic protocols are clearly defined but may not be systematically followed across centers, etc. In Phase 4, also non-academic memory clinics use the biomarker and contribute data for its validation. Usually, sample sizes are larger (hundreds) than those in Phase 3 (dozens).

All the primary and secondary aims for clinical validity are fully consistent with the 2017 framework.

**Clinical validity: 2020 update** Similar to the original framework proposed in 2001 for oncology, repositories of pertinent biological samples are now available and allow to perform retrospective longitudinal studies that were not possible in 2017 (the 2017 SBR only included “prospective” longitudinal studies). Moreover, it is clear at this time that a structured plan to define clinically meaningful outcomes is urgently needed to set the bases for proper Phase 5 studies (see the “Clinical utility” section; [30]).

**Clinical utility** In Phase 5, practical issues like implementability, health benefit, and cost-effectiveness are assessed specifically and systematically, leveraging the preliminary information collected in Phase 4. All primary and secondary aims of clinical utility are consistent with the 2017 framework.

**Clinical utility: 2020 update** The outcomes to be considered in the assessment of cost-effectiveness not only differ from those of oncology but are still scarcely defined for the field of AD itself [30]. The definition of outcomes should be relevant for end-users [31] and clinically meaningful [32]. Consensual definitions of clinical meaningfulness involving end-users are still lacking and should be formulated with priority, possibly within Phase 4 studies. Only studies assessing biomarker performance relative to clinically significant and patient-relevant endpoints can produce data that can enter evidence-to-decision (EtD) procedures for clinical and policy decision-making [31].

**Gold standard** Pathology is the required gold standard for Phases 1–2 assessing analytical validity. Ideally, pathological confirmation should be obtained at all validation steps in all phases. However, clinical progression at follow-up is used as an admissible reference standard for clinical validity studies (Phases 3–4).

**Gold standard: 2020 update** The inaccessibility of brain tissue led to admit reference standards as acceptable, despite warning, even in Phase 2 studies for different reasons. First, concrete hurdles hamper the performance of autopsy studies. Second, even when autopsy is performed, tissue examination may be too a long time apart from biomarker assessment in the relevant clinical phase (e.g., MCI), with weak connection between the two kinds of data. Third, at present, the ultimate
| Phase | Oncology | SBR 2017 AD (2011 criteria) | SBR 2020 AD (stage within A/T/N framework) | Aim |
|---|---|---|---|---|
| Analytical validity (target: assay) | Oncology | SBR 2017 AD (2011 criteria) | SBR 2020 AD (stage within A/T/N framework) | Oncology |
| Phase 1 | Preclinical exploratory studies | Phase 2 | Clinical assay development for clinical disease | Context of use: Purpose: screening and case finding Population: preclinical/at risk |
| Clinical validity (target: test performance) | Phase 3 | Retrospective longitudinal repository studies | Prospective longitudinal repository studies | Longitudinal repository studies |
| | Prospective screening studies | Prospective diagnostic studies | PA 1 | PA 2 |
| | | | SA 1 | SA 2 |
| | | | SA 3 | SA 4 |
| | | | | |
| Clinical utility | Phase 5 | Cancer control studies | Disease control studies | PA |
| | | | SA 1 | SA 2 |
| | | | SA 3 | SA 4 |

| Aim | Comments |
|---|---|
| Oncology | SBR 2017 AD (2011 criteria) | SBR 2020 AD (stage within A/T/N framework) | SBR 2017 | SBR 2020 |
| Analytical validity (target: assay) | Context of use: Purpose: screening and case finding Population: preclinical/at risk | Context of use: Purpose: diagnosis | Diagnostic criteria for Alzheimer’s disease are based on clinical features and include the use of biomarkers to Biomarker profiles combining amyloid, tauopathy, and neurodegeneration lie along an AD or non-AD continuum |
### Table 2 (continued)

| Purpose | Method | Design | Population | Reference standard |
|---------|--------|--------|------------|--------------------|
| To identify and prioritize leads for potentially useful biomarkers | Phase 2 assesses analytical validity, i.e., the ability of the assay to detect the alteration of interest | case-control | pathological specimens from any AD stage | (clinical progression at follow-up; positivity to another AD biomarker) is allowed due to limited accessibility to pathology. However, this is a key limitation in studies of analytical validity. Thus, the use of a reference standard in Phase 2 studies should be accepted with warning (*) |
| To estimate the true and false positive rate or ROC curve and assess its ability to distinguish subjects with and without the disease | | | | |
| To optimize procedures for performing the assay and to assess its reproducibility within/between laboratories | | | | |
| To determine the relationship between biomarker measurements made on tumor/brain tissue and the biomarker measurements made on the noninvasive clinical specimen | | | | |
| To assess factors (e.g., sex, age, etc.), associated with biomarker status or level in control subjects | | | | |
| To assess factors associated with biomarker status or level in diseased subjects—in particular, disease characteristics such as stage, histology, grade and prognosis | | | | |
| To assess factors associated with biomarker status or level in cognitively impaired subjects—in particular, disease characteristics such as stage, histology, grade, and prognosis | | | | |
| Clinical validity (target: test performance) | Clinical validity assesses the performance of the assay, developed in Phase 2, now used as a diagnostic test. Phase 3 studies are performed in well controlled experimental settings, examining cohorts from research | | | |
| | | | | |
| Population: patients referred/-ing to clinical centers due to cognitive complaints | increase the certainty on the etiological diagnosis of AD | | | |
| | | | | |
centers or academic memory clinics; the biomarker is assessed, but not used to formulate the clinical diagnosis for patients

**Outcome: case-control separation**
(sensitivity, specificity, true positive ratio, false positive ratio, and ROC curves)

To evaluate, as a function of time before clinical diagnosis, the capacity of the biomarker to detect preclinical disease

To evaluate, as a function of time in the prodromal stage (MCI), the capacity of the biomarker to predict conversion to AD dementia

**Design:** observational prospective longitudinal case-control studies (in the absence of nested case-control longitudinal cohorts allowing retrospective examination)

**Population:** MCI

**Gold standard:** pathology

**Reference standard:** progression to dementia at 3 years (if pathology is lacking)

**Outcome:** case-control separation

---

Design: in addition to the 2017 designs, cross-sectional studies, containing known risk factors for dementia (e.g., confirmed brain amyloidosis, APOE-e4, etc.) are admitted as contributing construct validity evidence. Moreover, repositories may now allow retrospective studies also for biomarkers for the diagnosis of neurocognitive disorders

**Gold standard:** clinical progression should not be considered just an acceptable reference standard in the lack of pathology but should be included in the definition of the gold standard (clinical progression + pathology).

**Reference standard:** consistently with the considerations on cross-sectional design, biomarker characterization or other features can contribute to construct validity. However, clinical progression generates stronger evidence than other reference standards based on construct validity.

**Outcome:** case-control separation
(sensitivity, specificity, true positive ratio, false positive ratio, and ROC curves)

---

"in preparation of Phase-4": in phase 3, the biomarker is assessed in strictly experimental conditions. Patients are tested, but their diagnosis is NOT based on the biomarker under examination. Here, the biomarker’s features are adjusted to allow its use for clinical diagnosis in Phase 4

Note the difference between Phase 3_SA1 and Phase 2_SA3–4: in phase 2, covariates are assessed relative to their effect on status or level of the biomarker and on the threshold for positivity, in order to define the assay. In Phase 3, covariates are explored relative to their effect on the discriminatory ability of the biomarker, i.e., in using the assay as a test
To compare markers to select the most promising

To develop algorithms for screening based on combinations of markers
Develop algorithms for the biomarker-based diagnosis of MCI in preparation of Phase 4

To determine a screening interval for Phase 4 if repeated testing is of interest
To determine an interval able to detect a meaningful change of biomarker status or level in progressing MCI

In Phase 4, the biomarker, still under investigation, is used also in non-academic clinical contexts to support patient diagnosis. The experimental use of the biomarker should be made explicit to patients. Phase 4 provides validation data on the use of the biomarker in real-world rather than strictly controlled conditions. Sample sizes are larger than in Phase 3

To determine the operating characteristics of the biomarker-based screening test in a relevant population by determining the detection rate and the false referral rate
To determine the operating characteristics of the biomarker-based diagnostic test in MCI patients in the memory clinics population

Design: prospective longitudinal studies (studies at this stage involve testing people and lead to diagnosis and treatment).
Population: same as Phase 3 (size: hundreds, from tertiary referral centers). Gold reference standard: like Phase 3
Outcome: proportion of cases correctly diagnosed; baseline correlates of biomarker positivity (age, severity, etc.); compliance with the program; disease-associated morbidity, quality of life, costs

To describe the characteristics of tumors detected by the screening test—in particular, with regard to the potential benefit incurred by early detection
To describe the characteristics of the neurodegenerative disorder detected by the diagnostic biomarker—in particular, with regard to the potential benefit incurred by early detection

To assess the practical feasibility of implementing the screening program and compliance of test-positive subjects with workup and treatment recommendations
To assess the practical feasibility of implementing the biomarker-based diagnostic procedure and compliance of test-positive subjects with workup recommendations.

The emotional and social implications related to positive test results within the diagnostic procedure may need to be assessed and taken into account, to increase compliance to workup recommendations. This was done in oncology, also based on a counseling
| Clinical utility | Outcome definition is still insufficient to cover this aim properly [30] and should be solved with priority |
|------------------|--------------------------------------------------------------------------------------------------|
|                  | To make preliminary assessments of the effects of screening on costs and burden associated with AD |
|                  | To monitor tumors occurring clinically but not detected by the screening protocol |
|                  | To monitor AD dementia/neurocognitive disorders occurring clinically but not detected by the biomarker-based diagnostic procedure |
| Phase 5 entails surveillance studies on thousands of subjects | To estimate the effects of biomarker-based diagnosis on disease-associated mortality, morbidity, and disability |
| Design: surveillance system of accepted practice | Population: = same as Phase 4 (size: thousands, from secondary referral centers) |
| Outcome: proportion of cases correctly diagnosed; baseline correlates of biomarker positivity (age, severity, etc.); compliance with the program; disease-associated morbidity, quality of life, costs |
| To estimate the reductions in cancer mortality afforded by the screening test | To obtain information about the costs of biomarker-based diagnosis per quality-adjusted years of life |
| To obtain information about the costs of screening and treatment and the cost per life saved | To evaluate compliance with biomarker-based diagnostic workup in a diverse range of settings. |
| To evaluate compliance with screening and workup in a diverse range of settings. | To compare different biomarker-based diagnostic protocols and/or to compare different approaches to treating biomarker-based diagnosed subjects in regard to effects on quality-adjusted years of life, mortality, and costs |

*AD Alzheimer’s disease, MCI mild cognitive impairment, PA primary aim, SA secondary aim. * In AD, tissue is not accessible as in other contexts, like oncology. We assessed Aims completion weighing such feasibility issues. However, especially in the Analytical Validity stage, aim achievement should be assessed in studies using pathology as the gold standard (see Table). “Achievement” without pathology should be considered “with warning” to underline such intrinsic limitation, and the need of producing or replicating this kind of evidence when feasible.
practical clinical interest focuses more on identifying persons with cognitive impairment who will probably progress to dementia, than on identifying the exact underlying pathology. Finally, we are developing an increasing awareness of the complexity of AD and related disorders [33], and, relative to clinical diagnosis, “progression to dementia” is considered by some as an even more appropriate gold standard than autopsy. This is even more true in the case of tau biomarkers: indeed, the A/T/N criteria not only require positivity to tau pathology to define clinical AD but also categorize individuals with positive tau and negative Aβ as belonging to the continuum of non-AD progressive neurodegenerative disorders (Table 2 in [1]). Since the context of use defined for the SBR consists of diagnosing people with MCI in memory clinics, this potential use of tau biomarkers should not be ruled out for not serving an AD diagnosis specifically. This set of reasons led to admit less stringent reference criteria as a mandatory methodological decision. We will use the term “reference standard” for the sake of methodological rigor, to indicate the lower level of evidence provided by the lack of confirmation of AD (or of other non-AD neurodegenerative disorders) at pathology, although some of the above reasons may support the use of clinical progression as no less appropriate for some goals. Relative to the use of clinical progression as a reference standard also for Phase 2 (very few studies with pathology could be performed for tau imaging to date) [34]. With progressing validation of AD biomarkers, positivity at an alternative AD biomarker can be used as a reference standard contributing construct validity, although this should be done only within the aims that are not intended to compare or combine different biomarkers. The evidence obtained using positivity to an alternative AD biomarker alone (or to other features, like APOE) is weaker than that provided by studies using clinical progression as reference standard. One reason is that the other biomarkers are still under investigation themselves, and without complete formal validation, they cannot become the new proper gold or reference standards. Moreover, the evidence so collected cannot be directly associated to a progressive neurodegenerative condition and, relatively to tau biomarkers, cannot account for non-AD neurodegenerative disorders. However, such studies can be taken into account as providing evidence of construct validity specifically to AD. Admitting such reference standard affects the study design to be considered: cross-sectional studies thus are eligible with the 2020 SBR, in addition to longitudinal studies.

Methods to perform the biomarker-specific reviews As in 2017, we asked young researchers from the involved expert groups to identify the clinical studies addressing the ABR aims, possibly on multiple databases (e.g., PubMed, Embase, and Cochrane; reviews were not included but used
to identify additional original article). Inclusion criteria for papers’ selection were as follows: (1) Manuscript type: full manuscript; (2) Population of interest: The target population was AD diagnosed according to validated clinical diagnostic criteria as defined in the Glossary; (3) Language and time span: only papers published in English and up to July 2020. Relevant previous literature from personal knowledge and tracked from reviews was included. Book chapters, conference abstract, and case reports were excluded.

**Methods to perform the biomarker-specific reviews: 2020 update** In order to make reviews more systematic than those performed in 2017, for each review we asked that an independent researcher replicate the literature search for random aims, to ascertain the replicability of findings, and check the data extraction accuracy. Based on the output, search strings as well as paper selection were updated to improve both searches and their replicability.

**Assessment of aim achievement** The fulfillment of each aim was assessed examining the available data with the same criterion used in the 2017 SBR (Fig. 1 and Legend to Fig. 1).

**Assessment of aim achievement: 2020 update** In addition to the 2017 assessment, we included the possibility of coding possible failures along the validation course (purple box in Fig. 1): namely, an aim can be defined *Unsuccessful*, when evidence is available, demonstrating that the biomarker failed the validation step. Although our method to assess aim achievement (See Fig. 1 legend) does address somehow the adequacy of studies’ methodology, this is weak and liable to bias. Therefore, in addition to this reference assessment criteria, we have provided tables structuring data extraction and reporting based on methodological guidance for formal evidence assessment [18, 35, 36] and on previous adaptations to diagnostic biomarkers for AD [37] (see Supplemental Material at https://drive.switch.ch/index.php/s/4reUTSuqNZHyIC8). Indeed, proper evidence assessment requires specific analyses [18, 35, 36] thoroughly assessing risks of bias and other parameters possibly increasing (e.g., strong effect) or decreasing (e.g., large confidence intervals) the quality of the produced evidence. While such assessment goes beyond the aim of the current initiative, we nonetheless deemed relevant to set the bases and facilitate a future development towards such formal evidence assessment. Thus, we have provided tables for data extraction and we asked the researchers performing the reviews to fill them and report the main features that allow for better understanding and assessment of potential biases (e.g., limited sample size, lack of matched controls, case-control in place of cohort design study, reference standard in place of gold standard, lack of blinding in the assessment of biomarkers, short follow-up duration or excessive number of drop outs, etc.) [18, 36]. These tables, adapted from previous evidence assessment for diagnostic biomarkers for neurocognitive disorders [37], are filled with the data extracted from the studies included in the reviews—[25–29]—and made available to the readers to complement our overall assessment (https://drive.switch.ch/index.php/s/4reUTSuqNZHyIC8).

**Discussion**

In this work, we have revised the 2017 Biomarker Roadmap methodology [13, 14] to allow for the assessment of biomarkers of tauopathy, as well as that of the other diagnostic biomarkers of AD and related disorders, consistently with the 2018 A/T/N research framework. Most of the 2017 methodology remains valid (the Biomarker Roadmap was first launched late in 2014): aligning to the A/T/N framework [1] did not significantly affect the context of use (besides a more explicit inclusion of non-AD conditions), since the validation of diagnostic biomarkers is currently aimed to a clinical use and relies necessarily on a clinical definition of the target disorder. However, we have admitted a larger variety of reference standards based on construct validity, consistent with increasingly acknowledged complexity [33] and an atheoretical approach. Also, under the light of recent studies, we have clarified some methodological issues to provide guidance in applying the SBR while performing new research or assessing available validation studies of diagnostic biomarkers for AD. Finally, we have outlined research priorities for the next validation studies (e.g., the need to define clinical outcomes to assess societal impact in Phase 5). This work leverages previous efforts, namely, in oncology [15] and on the 2017 SBR [13, 14], and tries to capitalize on requirements for ultimate implementation of biomarkers in clinics based on the methodological constraints for regulatory purposes [18, 31, 35, 36].

**Role of tau biomarkers** The A/T/N criteria define a clear role of tau biomarkers in the diagnostic procedure of patients complaining about cognition. In particular, (a) their positivity is required to define *clinical AD*, and (b) their positivity in Aβ-negative patients denotes the presence of a neurodegenerative disorders belonging to a non-AD continuum. These are the main features underlying the need for a revision of the SBR. The informative value of biomarkers of tauopathy for either AD or non-AD neurodegenerative disorders is helpful for clinical use; therefore, this methodology is generically aimed at detecting AD, but is not meant to exclude other dementing neurodegenerative disorders.

**Wider set of reference standards admissible to assess aim achievement** The limited accessibility to brain histology hinders the availability of the gold standard for AD biomarkers;
limitations in following up patients, as well as inconsistencies in the assessment of progression across clinics, limit the validity and reliability of the detection of conversion to dementia and of its use as a satisfactory reference standard. However, our evolving construct of AD and the progressing validation of other AD biomarkers allow to consider additional reference standards (e.g., positivity to other AD biomarkers, to APOE-ε4, etc.). These can support the validation of AD biomarkers through cross-sectional studies. The downside of this approach is that such studies produce evidence with heterogeneous levels of strength, which needs therefore to be weighted when assessing the achievement of the validation aims.

**Evidence assessment: a mandatory step** When it comes to evidence-based decisions, published evidence must be examined based on formal evidence assessment [36]. This is originally thought to serve clinical and policy decision-making. However, this relates also to our effort of assessing aim achievement based on the SBR. In this initiative, we have still assessed aim achievement based on the 2017 criteria (Legend to Fig. 1) for the sake of feasibility. However, this approach is limited for different reasons. First, the criteria for achievement disregard a formal evidence assessment of all possible risks of bias; second, the introduction of different kinds of reference standards requires to weight the different strength of the produced evidence; third, this whole assessment should be done by methodologists with specific background, and not involved in the validation of the assessed biomarkers themselves. Despite the current limitations, we have structured a detailed data extraction, adapted to our specific context as recommended by evidence assessment approaches like GRADE [35, 36] and QUADAS [38] (https://drive.switch.ch/index.php/s/4eUTSuqNZHyIC8) as a step forward, and invited the researchers tasked with the review search to fill the data extraction files. This should enable the readers, independent methodologists, or future initiatives, to perform a formal assessment of the strength of the evidence of current data, and may serve next developments of the SBR.

A methodological resource in support of both reporting and study design may be provided by promoting compliance to the available reporting guidelines (https://www.equator-network.org; https://www.equator-network.org/?post_type=eq_guidelines&eq_guidelines_study_design=diagnostic-prognostic-studies&eq_guidelines_clinical_specialty=0&eq_guidelines_report_section=0&_= ). Methodological research priorities may include ascertaining whether these guidelines exhaustively reflect SBR aims specific to biomarkers for dementing neurodegenerative disorders, and either adapt them, or, if already adequate, promote their use in the field. In this initiative, we have complied with reporting guidelines for the reviews performed to assess the specific biomarkers [39]. Then, the tables for data extraction may be refined consistently. Meanwhile, our tables can provide, besides the assistance to evidence assessment, also an interim guidance to structure the reporting of the information specifically required to produce data eligible to EtD [18, 31, 35, 36].

**Research priorities for the methodological development of the SBR** Although the steps of the SBR were defined in a rather systematic way, key components are still missing and should be considered methodological priorities. For example, there is no agreement on the definition, selection, and assessment of the outcomes allowing reliable assessment of the impact of diagnostic biomarkers, meant to assess clinical utility in Phases 4–5 [30]. The currently used measures of biomarkers’ diagnostic accuracy or physicians’ diagnostic confidence are only indirectly connected with the clinically relevant and patient-relevant outcomes required by regulators [31, 32, 35, 40], and these are in turn far from being consensually agreed upon. Defining such outcomes is particularly urgent, since most AD biomarkers are already being validated in Phase 4 studies. Relative to Phase 4, we also underline that in this phase, biomarkers are not only evaluated in real-world clinical contexts but are also used to support patients’ diagnosis in such contexts. The still experimental use of such biomarkers should be made explicit to patients [41], and protocols for proper communication of the concept of risk, and of diagnosis itself, should be developed. As for the research methodology [15], other medical fields may also in this case serve as a guide (e.g., genetics for the communication of risk; oncology for the communication of diagnosis and counseling).

**Ultimate benefit of complying with the SBR** Complying with the SBR implies following the validation steps in the outlined order and with the study designs and kinds of variables detailed in Table 2. Lack of compliance with any of these characteristics leads to include variability and gaps that cannot be amended post hoc and that ultimately determine the ineligibility of available data to evidence-based procedures for decision-making [17, 37]. Complying with the SBR validation steps, sequence, and methodology is therefore necessary to collect proper evidence having sufficiently high quality to support the downstream implementation of biomarkers into practice. The reviews assessing the validation status of biomarkers and mapping gaps and research priorities—[25–29]—are meant to detect gaps early on in the validation procedure and inform on how to adjust it, before extensive efforts are deployed in downstream studies that would provide faulty or biased data. Thus, keeping the methodology updated and performing periodical assessments of validation proceedings can improve the cost-effectiveness of biomarker validation.

**Limitations** The major limitation of the whole initiative consists of the difficulty to access brain tissue and the rare
availability of pathology data providing the gold standard. This limitation is particularly important for the phase of analytical validity. To overcome this hurdle and proceed to the validation of diagnostic biomarkers for dementing neurodegenerative disorders, we have admitted positivity to other biomarkers in virtue of construct validity. However, the use of other biomarkers is not always possible (e.g., when different biomarkers are themselves object of comparison, e.g., in Phase 3, secondary aims 2 and 3). Moreover, such use is anyway subject to potential circularity: all biomarkers are still under investigation, and they would provide a reference standard for a specific disease (e.g., AD rather than other disorders that do not lie on the AD continuum, but still have tau positivity) based on our current (but not necessarily final) construct of AD. The alternative solution of clinical progression is apparently weaker, but actually sensible. Indeed, the ultimate clinical target consists of detecting progressive neurodegenerative disorders. Especially for biomarkers of tauopathy, clinical progression properly includes non-AD neurodegenerative disorders, consistently with the A/T/N criteria. However, in this case the limitation consists in possible heterogeneous measurements of progression across studies, weakening its validity and reliability and hampering comparability. Relative to the methods for performing the reviews, besides the mentioned limitations consisting of the lack of formal evidence assessment performed by independent methodologists, we also underline that the SBR effort has a relatively limited power to synchronize validation studies performed by independent groups. Working independently and on heterogeneous datasets, biomarker validation cannot proceed in a perfectly systematic way. Availability of datasets containing information for Phase 4 studies, for example, leads to initiate such studies despite incomplete evidence from previous phases. This problem is not unique to the AD field; however, measures may be taken to limit such mismatched proceeding and help integrate gaps in support of the whole process (see, e.g., the production of recommendations [42, 43], to support clinicians in a most rationale [44] use of such biomarkers in the lack of evidence for their combined use; such recommendations increase the reliability of clinical procedures as well as the consistency of the data that are collected in clinics and also used for research purposes). Finally, the A/T/N criteria are meant for research, and not for clinical diagnostic use; however, the whole theoretical and research effort on diagnostic biomarkers aims to the ultimate aim of improving clinical procedures for patients. Using the most advanced theories available to improve the methodology for validating biomarkers, while keeping into account the final concrete goal, can lead to apparent inconsistencies, for example, the validation of tau biomarkers for supporting AD diagnoses, but also the diagnosis of non-AD neurodegenerative disorders.

Conclusions
The field of AD diagnostic biomarkers is progressively approaching that of oncological biomarkers [15]. With the A/T/N framework, biomarkers are examined and assessed for their individual contribution to an AD or non-AD profiles, allowing more precise diagnosis that is more independent on specific theories on AD pathogenesis; the availability of sample repositories now allows studies with retrospective design in addition to the only prospective studies of MCI clinical trajectory; and most recent biomarkers like those extracted from plasma [29] allow to envision validation procedures for the different contexts of use, entailing preclinical stages, or screening or case finding purposes, like in oncology. The present effort is still limited to the diagnosis of patients with objective clinical impairment in specialist settings (memory clinics); however, validation studies relative to other contexts of use, which need to be assessed with specific reference to such different contexts, are increasingly conceivable. Future efforts may import methodology and validation status of Phases 1–2 of the current SBR as such, since the methodology of diagnostic studies assessing the performance of new assays is standardized whatever the contexts and adapt the framework for consistent data generation and assessment from Phase 3. On the whole, these future advances will further develop the research of AD diagnostic biomarkers consistently with the oncological model and in the direction of precision medicine.

Collaborators: Henryk Barthel1, Julie Corre2, Matteo Cotta-Ramusino3, Jean-François Demonet2, Anton Gietl6, Thomas K Karikari7, Marco Lorenzi5, Osama Ratib5, Valérie Teyrey10, Paul G Unschuld11-4, Layla Sbrizzi1, Jean-François Demonet2, Anton Gietl6, Thomas K Karikari7, Marco Lorenzi5, Osama Ratib5, Valérie Teyrey10, Paul G Unschuld11-4, 1Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany 2CNRS - Centre National de la Recherche Scientifique, Montpellier, France 3Department of Brain and Behaviour, University of Pavia, Pavia, Italy 4Unit of General Neurology, IRCCS Mondino Foundation, Pavia, Italy 5Leenaards Memory Centre, Department of clinical neurosciences, University Hospital Centre (CHUV) and University of Lausanne (UNIL), Switzerland 6Institute for Regenerative Medicine (IREM), University of Zurich, Schlieren, Switzerland 7Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden 8Epione Team, Inria Sophia Antipolis, Sophia Antipolis, France 9Nuclear Medicine and Molecular Imaging Division, Department of Medical Imaging, University Hospitals of Geneva, Genève, Switzerland 10Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland 11Division of Geriatric Psychiatry, University Hospital of Geneva (HUG), Geneva, Switzerland, 12Institute for Regenerative Medicine (IREM), University of Zurich, Schlieren, Switzerland, 13Psychiatric University Hospital Zurich (PUK), Zurich, Switzerland, 14Institute for Biomedical Engineering (IBT), ETH, Zurich, Switzerland.
Funding  Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Swiss National Science Foundation (grant n. IZSEZ0_188355; recipient: V. Garibotto), by the Alzheimer’s Association, by the OsiRN Foundation, and by the APRA (Association Suisse pour la Recherche sur l’Alzheimer).

V. Garibotto was also supported by the Swiss National Science Foundation (projects 320030_169876 and 320030_185028) and by the Velux foundation (project 1123).

M. Boccardi was supported in part by the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (grant no. 115952; recipient: Giovanni Frisoni).

Compliance with ethical standards

Conflict of interest  V. Garibotto received financial support for research through her institution from Siemens Healthineers, GE Healthcare, Life Molecular Imaging, Cereveau Technologies, Roche, Merck.

O. Hanssom has acquired research support (for the institution) from Roche, Pfizer, GE Healthcare, Biogen, Eli Lilly and AVID Radiopharmaceuticals. In the past 2 years, he has received consultancy/speaker fees from Biogen, Roche and AC Immune.

G.D. Rabinovici receives research support from the National Institutes of Health, Alzheimer’s Association, American College of Radiology, Rainwater Charitable Foundation, Gift from Edward and Pearl Fein, Avid Radiopharmaceuticals, Eli Lilly, Life Molecular Imaging, GE Healthcare. He has served as a consultant for Axon Neurosciences, Eisai, GE Healthcare, Merck, Genentech. He serves on a data safety monitoring board for Johnson & Johnson. He is an associate editor for JAMA Neurology.

Authors Marina Boccardi, Alessandra Dodich, Emiliano Albanese, Angèle Gayet-Ageron, Cristina Frestari, Nicholas J Ashton, Gérard N Bischof, Konstantinos Chiotis, Antoine Leuzy, Emma E Wolters, Martin Walter, Maria Carrillo, Alexander Drzezga, Agneta Nordberg, Rik Ossenkoppele, Victor L Villemagne, Bengt Winblad, and Giovanni Frisoni report no conflict of interest.

Research involving human participants and/or animals  This work entirely consists of methodological requirements and did not involve human or animal participants.

Informed consent  Not applicable (the work did not involve human nor animal participants).

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Jack CR. B. NIA-AA research framework: towards a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.

2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34(7):939–44.

3. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.

4. James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia. Brain J Neurol. 2016;139(11):2983–93.

5. Kovacs GG, Milenkovic I, Wöhrer A, Höftberger R, Gelpi E, Haberler C, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol (Berl). 2013;126(3):365–84.

6. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer disease centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71(4):266–73.

7. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59(2):198–205.

8. Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiang MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain J Neurol. 2008;131(Pt 3):665–80.

9. Abner EL, Kryscio RJ, Schmitt FA, Fardo DW, Moga DC, Igbdaro ET, et al. Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Ann Neurol. 2017;81(4):549–59.

10. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian imaging, biomarker and lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275–83.

11. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29.

12. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.

13. Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, et al. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol. 2017;16(8):661–76.

14. Boccardi M, Gallo V, Yasiu Y, Vineis P, Padovan A, Mosimann U, et al. The biomarker-based diagnosis of Alzheimer’s disease. Lessons from oncology. Neurobiol Aging. 2017;52:141–52.

15. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93(14):1054–61.

16. Frisoni GB, Jack CR, Bocchetta M, Bauer C, Frederiksen KS, Liu Y, et al. The EADC-ADNI harmonized protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimers Dement. 2015;11(2):111–25.

17. Smalagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekitis C. (1)18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;1:CD010632.
18. Twells LK. Evidence-based decision-making 1: critical appraisal. In: Parfrey PS, Barrett BJ, editors. Clinical Epidemiology [Internet]. New York, NY: Springer New York; 2015 [cited 2 April 2020]. pag. 385–96. (Methods in Molecular Biology; vol. 1281). Available at: http://link.springer.com/10.1007/978-1-4939-2428-8_23.

19. Cerami C, Dubois B, Boccardi M, Monsch AU, Dement EF, Cappa SF. Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:153–66.

20. Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214–27.

21. Mattsson N, von Neuenburg A, Boccardi M, Blennow K, Hansson O. Clinical validity of cerebrospinal fluid Abeta42, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:196–213.

22. Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR, Lovblad KO, et al. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:167–182.e1.

23. Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, et al. Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:193–85.

24. Sonni I, Ratib O, Boccardi M, Picco A, Herholz K, Nobili F, et al. Clinical validity of presynaptic dopaminergic imaging with 18F-flutemetamol and 18F-flortaucipir as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:228–42.

25. Wolters E, Dodich A, Boccardi M, et al. Clinical validity of increased cortical uptake of 18F-Flortaucipir as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. 2020. https://doi.org/10.1007/s00259-020-05118-w.

26. Chiotis K, Dodich A, Boccardi M, et al. Clinical validity of increased cortical uptake of tau ligands of the THK family and 11C-PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. 2020. https://doi.org/10.1007/s00259-021-05277-4.

27. Bishop G, Dodich A, Boccardi M, et al. Clinical validity of increased cortical uptake of second-generation Tau PET tracers as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. 2020. https://doi.org/10.1007/s00259-020-05156-4.

28. Leuzy A, Ashton N, Dodich A, et al. 2020 Update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. 2020. https://doi.org/10.1007/s00259-021-05258-7.

29. Ashton N, Leuzy A, Karkari TK, et al. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. 2020. https://doi.org/10.1007/s00259-021-05253-y.

30. Cotta Ramusino M, Alomare D, Perini G, et al. Outcomes of clinical utility for Alzheimer’s disease diagnostic biomarkers: state of art and future perspectives. 2020. https://doi.org/10.1007/s00259-020-05187-x.

31. Leon MA, Brainin M, Boon P, Pugliatti M, Keindl M, Bassetti CL. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012. Eur J Neurol. 2013;20(3):410–9.

32. EMA. Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease. European Medicine Agency; 2018.

33. Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath TV, et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease. Nat Med. 2020;26(8):1256–63.

34. Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77(7):829–39.

35. Guyatt G, Oxman AD, Akhtar M, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.

36. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407–15.

37. Boccardi M, Fustari C, Altomare D, Gandolfò F, Orini S, Nobili F, et al. Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. Eur J Nucl Med Mol Imaging. 2018;45(9):1470–86.

38. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.

39. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12.

40. FDA. Early Alzheimer’s disease: developing drugs for treatment guidance for industry. Food and Drug Administration; 2018.

41. Porteri C, Albanese E, Scerri C, Carrillo MC, Snyder HM, Truocchio SP, et al. Positron emission tomography imaging with 18F-flortaucipir in Alzheimer disease: developing drugs for treatment guidance for industry. Food and Drug Administration; 2018.

42. Frisoni GB, Perani D, Bastianello S, Bernardi G, Porteri C, Boccardi M, et al. Biomarkers for the diagnosis of Alzheimer’s disease in clinical practice: an Italian intersocietal roadmap. Neurobiol Aging. 2017;52:132–40.

43. Porteri C, Albanese E, Scerri C, Carrillo MC, Snyder HM, Truocchio SP, et al. Positron emission tomography imaging with 18F-flortaucipir in Alzheimer disease: developing drugs for treatment guidance for industry. Food and Drug Administration; 2018.

44. Boccardi M, Nicolosi V, Fustari C, Bianchetti A, Cappa S, Chiasserini D, et al. Italian consensus recommendations for the biomarker-based etiological diagnosis of Alzheimer’s disease. 1-ethical and societal issues. Neurobiol Aging. 2017;52:132–40.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Affiliations

Marina Boccardi1,2 · Alessandra Dodich3,4 · Emiliano Albanese5 · Angèle Gayet-Ageron6 · Cristina Festari7 · Nicholas J. Ashton8,9,10,11 · Gérard N. Bischof12 · Konstantinos Chiotis13,14 · Antoine Leuzy13 · Emma E. Wolters15 · Martin A. Walter16 · Gil D. Rabinovici17 · María Carrillo18 · Alexander Drzezga19,20,21 · Oskar Hansson22,23 · Agneta Nordberg13,24 · Rik Ossenkoppele15,25 · Victor L. Villemagne26,27 · Bengt Winblad24,28 · Giovanni B. Frisoni22,29 · Valentina Garibotto4,16

1 German Center for Neurodegenerative Diseases DZNE-Standort Rostock/Greifswald, Gehlsheimer Str. 20, 18147 Rostock, Germany
2 LANVIE - Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland
3 Center for Neurocognitive Rehabilitation (CeRiN), CIMeC, University of Trento, Trento, Italy
4 NIMTlab - Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, Switzerland
5 USI – Università della Svizzera Italiana, Institute of Public Health (IPHI), Lugano, Switzerland
6 Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva & University Hospitals of Geneva, Geneva, Switzerland
7 LANE – Laboratory of Alzheimer’s Neuroimaging and Epidemiology, IRCCS Istituto San Giovanni di Dio Fatebenefratelli, Brescia, Italy
8 Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden
9 Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at The University of Gothenburg, Mölndal, Sweden
10 NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK
11 Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
12 Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany
13 Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
14 Theme Neurology, Karolinska University Hospital, Stockholm, Sweden
15 Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
16 Nuclear Medicine and Molecular Division, Geneva Medical Hospital, Geneva, Switzerland
17 Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco, CA, USA
18 Alzheimer’s Association, Chicago, IL, USA
19 Faculty of Medicine, University of Cologne, Cologne, Germany
20 German Center for Neurodegenerative Diseases (DZNE), Bonn/ Cologne, Germany
21 Molecular Organization of the Brain, Research Center Jülich, Institute of Neuroscience and Medicine (INM-2), Jülich, Germany
22 Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden
23 Memory Clinic, Skåne University Hospital, Malmö, Sweden
24 Karolinska University Hospital, Theme Aging, Geriatric Clinic, Huddinge, Sweden
25 Department of Clinical Memory Research, Lund University, Lund, Sweden
26 Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia
27 Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
28 Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden
29 Memory Clinic, University Hospital, Geneva, Switzerland